Indraprastha Medical Corporation (INDRAMEDCO)₹331.50−1.70%Hospital
In the Jun 2026 quarter (standalone), Indraprastha Medical Corporation reported sales of ₹407 Cr, up 11.2% from Jun 2025, and net profit of ₹55.94 Cr, up 9.8% year on year. For the year to Mar 2026, sales were ₹1,486 Cr and net profit ₹184 Cr.
Company filings, standalone accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 317 | 306 | 315 | 349 | 351 | 326 | 334 | 366 | 381 | 372 | 366 | 407 |
| Expenses | 267 | 259 | 265 | 281 | 286 | 273 | 272 | 292 | 310 | 310 | 304 | 326 |
| Operating Profit | 49.90 | 46.91 | 47.86 | 66.86 | 63.87 | 51.92 | 60.85 | 72.79 | 70.88 | 61.87 | 60.88 | 79.84 |
| OPM % | 16.0% | 15.1% | 15.0% | 19.1% | 18.1% | 16.1% | 18.0% | 20.0% | 19.1% | 17.1% | 17.0% | 20.0% |
| Other Income | 4.01 | 4.01 | 5.01 | 5.01 | 6.01 | 5.01 | 6.02 | 7.02 | 7.02 | 7.02 | 7.01 | 8.02 |
| Interest | 1.01 | 1.01 | 2.01 | 2.01 | 2.01 | 2.01 | 1.01 | 2.01 | 2.01 | 1.01 | 1.01 | 2.01 |
| Depreciation | 10.01 | 9.99 | 9.99 | 11.01 | 11.01 | 11.01 | 11.01 | 10.01 | 11.01 | 11.01 | 11.01 | 12.01 |
| Profit before tax | 43.95 | 41.01 | 41.97 | 59.99 | 57.02 | 44.95 | 54.96 | 68.01 | 65.93 | 55.99 | 54.95 | 75.01 |
| Tax % | 25.0% | 28.0% | 24.9% | 25.0% | 25.9% | 26.0% | 25.9% | 25.0% | 25.0% | 27.0% | 24.0% | 24.9% |
| Net Profit | 32.97 | 28.94 | 30.97 | 44.92 | 41.97 | 32.95 | 40.95 | 50.95 | 48.91 | 40.92 | 41.97 | 55.94 |
| EPS (Rs) | 3.59 | 3.22 | 3.41 | 4.89 | 4.64 | 3.59 | 4.48 | 5.63 | 5.42 | 4.48 | 4.56 | 6.12 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 757 | 767 | 754 | 789 | 832 | 614 | 889 | 1,100 | 1,247 | 1,358 | 1,486 | 1,526 |
| Expenses | 674 | 686 | 677 | 705 | 742 | 572 | 767 | 946 | 1,048 | 1,110 | 1,214 | 1,249 |
| Operating Profit | 79.84 | 78.84 | 73.83 | 81.81 | 86.74 | 40.93 | 120 | 152 | 194 | 244 | 267 | 273 |
| OPM % | 11.1% | 10.1% | 10.1% | 10.1% | 11.1% | 7.0% | 14.0% | 14.0% | 16.0% | 18.0% | 18.0% | 17.9% |
| Other Income | 1.01 | 0.00 | −1.01 | −1.01 | 0.00 | 0.00 | −3.01 | 9.02 | 16.05 | 22.06 | 29.05 | 29.07 |
| Interest | 7.02 | 8.01 | 9.01 | 7.02 | 6.01 | 3.01 | 3.01 | 4.01 | 4.01 | 6.01 | 6.01 | 6.04 |
| Depreciation | 35.01 | 30.99 | 30.99 | 30.02 | 32.99 | 33.04 | 35.04 | 39.02 | 39.99 | 44.04 | 44.05 | 45.04 |
| Profit before tax | 39.01 | 40.97 | 33.97 | 45.01 | 48.01 | 3.99 | 78.98 | 117 | 166 | 216 | 246 | 252 |
| Tax % | 37.0% | 35.9% | 37.9% | 35.9% | 9.0% | 45.9% | 26.0% | 26.0% | 24.9% | 25.9% | 25.0% | — |
| Exceptional items | −1.01 | 0.00 | −1.01 | −1.01 | −1.01 | 0.00 | −4.01 | −1.01 | −1.01 | 0.00 | 0.00 | — |
| Net Profit | 23.97 | 25.95 | 20.96 | 27.97 | 43.92 | 1.99 | 58.96 | 85.95 | 124 | 161 | 184 | 188 |
| EPS (Rs) | 2.67 | 2.87 | 2.31 | 3.11 | 4.78 | 0.26 | 6.41 | 9.43 | 13.57 | 17.61 | 20.09 | 20.58 |
| Dividend payout % | 68.0% | 63.1% | 65.0% | 52.0% | 0.0% | 0.0% | 39.0% | 32.0% | 33.0% | 26.0% | 20.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 92.31 | 92.39 | 92.39 | 92.35 | 92.33 | 92.39 | 92.32 | 92.42 | 92.24 | 92.32 | 92.25 | 92.10 |
| Reserves | 103 | 132 | 139 | 141 | 152 | 176 | 181 | 234 | 288 | 386 | 506 | 649 |
| Borrowings | 49.92 | 51.99 | 66.92 | 65.95 | 20.97 | 3.99 | 2.99 | 4.99 | 1.99 | 33.94 | 32.94 | 36.90 |
| Other Liabilities | 195 | 185 | 160 | 134 | 156 | 177 | 157 | 130 | 172 | 211 | 221 | 213 |
| Total Liabilities | 442 | 460 | 458 | 432 | 422 | 449 | 432 | 462 | 554 | 722 | 852 | 990 |
| Fixed Assets | 286 | 302 | 297 | 295 | 280 | 304 | 284 | 278 | 275 | 348 | 329 | 366 |
| CWIP | 2.99 | 2.99 | 0.00 | 0.00 | 0.99 | 0.00 | 2.99 | 0.00 | 2.99 | 0.00 | 32.95 | 2.99 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 152 | 157 | 163 | 138 | 140 | 145 | 145 | 184 | 277 | 375 | 490 | 622 |
| Inventories | 12.01 | 9.99 | 10.01 | 8.99 | 7.99 | 12.01 | 9.01 | 10.01 | 7.99 | 8.01 | 7.01 | 8.01 |
| Trade receivables | 77.91 | 84.90 | 97.89 | 83.90 | 75.89 | 78.89 | 67.01 | 42.96 | 67.90 | 58.01 | 74.99 | 112 |
| Cash & equivalents | 6.01 | 6.01 | 7.01 | 8.01 | 22.05 | 24.05 | 28.04 | 68.18 | 129 | 224 | 322 | 264 |
| Total Assets | 442 | 460 | 458 | 432 | 422 | 449 | 432 | 462 | 554 | 722 | 852 | 990 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 63.90 | 61.88 | 27.97 | 47.92 | 74.94 | 85.86 | 26.98 | 93.92 | 144 | 200 | 157 | 167 |
| Cash from investing activity | −28.96 | −32.95 | −21.97 | −29.97 | −16.96 | −39.91 | −18.97 | −73.82 | −108 | −158 | −111 | −178 |
| Cash from financing activity | −34.89 | −29.93 | −4.99 | −16.97 | −43.91 | −42.93 | −2.99 | −2.99 | −25.92 | −31.93 | −45.89 | −45.88 |
| Net cash flow | 0.00 | 0.00 | 0.00 | 0.99 | 13.96 | 3.99 | 4.98 | 16.95 | 10.96 | 8.97 | 0.00 | −56.80 |
| Capex | 30.01 | 33.05 | 23.03 | 31.05 | 17.02 | 41.02 | 21.03 | 29.05 | 45.04 | 69.11 | 36.02 | 60.09 |
| Free cash flow | 35.03 | 28.99 | 5.01 | 17.01 | 57.96 | 46.03 | 6.01 | 64.99 | 100 | 131 | 120 | 108 |
| CFO / OP % | 98.1% | 104.1% | 57.1% | 82.1% | 110.0% | 113.1% | 88.1% | 95.1% | 102.1% | 127.1% | 89.0% | 88.1% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 41 | 42 | 48 | 42 | 36 | 36 | 41 | 19 | 24 | 18 | 21 | 29 |
| Inventory days | — | — | — | — | — | — | — | — | — | — | — | 11 |
| Days payable | — | — | — | — | — | — | — | — | — | — | — | 183 |
| Cash conversion cycle | 40 | 41 | 47 | 41 | 35 | 35 | 40 | 18 | 23 | 17 | 20 | −144 |
| Working capital days | −35 | −22 | −17 | −7 | −5 | −10 | −1 | −2 | −12 | −24 | −19 | −4 |
| ROCE % | 23.0% | 18.0% | 17.0% | 15.0% | 19.0% | 21.0% | 3.0% | 29.0% | 34.0% | 38.0% | 39.0% | 36.0% |
For the Jun 2026 quarter, Indraprastha Medical Corporation reported sales of ₹407 Cr, up 11.2% year on year and net profit of ₹55.94 Cr, up 9.8% year on year. The operating margin was 20.0%.
Indraprastha Medical Corporation's sales for the year to Mar 2026 were ₹1,486 Cr; over the last twelve months they were ₹1,526 Cr.
Net profit for the year to Mar 2026 was ₹184 Cr, and ₹188 Cr over the last twelve months. Earnings per share over the same trailing period were ₹20.58.
Indraprastha Medical Corporation reported borrowings of ₹36.90 Cr at Mar 2026, against cash and equivalents of ₹264 Cr.
Cash from operations was ₹167 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹108 Cr.